When Early Efficacy Data Forces a Site Ramp You Weren’t Budgeted For
Aprea's APR-1051 early signals are forcing a rapid site expansion—here's what the enrollment acceleration actually costs at the operational...
When a Failed Primary Endpoint Teaches More Than a Win: What CARDIOTTRansform’s Secondary Analysis Reveals About Stratification in Complex Trials
CARDIOTTRansform missed its primary endpoint, but its secondary analysis of eplontersen in ATTR-CM patients on background stabilizers is reshaping...
Ascletis Doses First Patient in ASC30 Phase III Obesity Trial
Ascletis doses first patient in ASC30 Phase III obesity trial, advancing oral GLP-1 agonist against established semaglutide competition through...
Lecanemab’s At-Home Start Dose Just Rewrote the Rules for Alzheimer’s Trial Design
FDA's July 2026 approval of at-home subcutaneous lecanemab initiation eliminates the 18-month IV requirement, reshaping CNS trial recruitment and...
enVast Mechanical Thrombectomy Meets Primary Endpoint in Large-Thrombus STEMI Trial
Mechanical thrombectomy for STEMI with large thrombus burden reduced infarct size by 26% in the NATURE trial, meeting its...
Dubai’s rWGS Scale-Up Rewrites the Diagnostic Playbook — But the Data Infrastructure Problem Stays Unsolved
Dubai Health's rapid whole-genome sequencing rollout for critically ill children delivers diagnostic yields that dwarf standard testing, but exposes...
Cumberland Seeks FDA Action on Ifetroban DMD Data Before Extension Study Complete
Cumberland Pharmaceuticals seeks FDA action on ifetroban DMD data from an ongoing extension study, positioning the drug for cardiomyopathy...
The FDA Alignment Playbook Behind Ocular Therapeutix’s Single-Trial NDA
How Ocular engineered a retinal drug program backward from approval, and what that means for every sponsor still designing...
Reading the COMPARE Phase 1 Data in Nature Medicine Closely
Nature Medicine's COMPARE phase 1 data on CD19 CAR T in refractory RA shows zero severe CRS in 6...
Akeso’s ivonescimab meets OS endpoint in EGFR-TKI-resistant NSCLC Phase III
Akeso's ivonescimab met overall survival endpoint in Phase III trial for EGFR-TKI-resistant NSCLC, with consistent results across Western and...